دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life:The SILENCE Randomized Clinical Trial
Harriëtte J. van Esch, MD1,2,3; Lia van Zuylen, MD, PhD1,4; Eric C. T. Geijteman, MD, PhD1; Esther Oomen-de Hoop, PhD1; Bregje A. A. Huisman, MD5; Heike S. Noordzij-Nooteboom, MD6; Renske Boogaard, RN7; Agnes van der Heide, MD, PhD2; Carin C. D. van der Rijt, MD, PhD1
doi : 10.1001/jama.2021.14785
JAMA. 2021;326(13):1268-1276
Death rattle, defined as noisy breathing caused by the presence of mucus in the respiratory tract, is relatively common among dying patients. Although clinical guidelines recommend anticholinergic drugs to reduce the death rattle after nonpharmacological measures fail, evidence regarding their efficacy is lacking. Given that anticholinergics only decrease mucus production, it is unknown whether prophylactic application may be more appropriate.
Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD ExacerbationA Randomized Clinical Trial
David Jiménez, MD, PhD1,2,3; Alvar Agustí, MD, PhD4; Eva Tabernero, MD5; Luis Jara-Palomares, MD, PhD6; Ascensión Hernando, MD, PhD7; Pedro Ruiz-Artacho, MD, PhD3,8; Gregorio Pérez-Peñate, MD, PhD9; Agustina Rivas-Guerrero, MD10; María Jesús Rodríguez-Nieto, MD, PhD3,11; Aitor Ballaz, MD12; Ramón Agüero, MD13; Sonia Jiménez, MD14; Myriam Calle-Rubio, MD, PhD15; Raquel López-Reyes, MD16; Pedro Marcos-Rodríguez, MD17; Deisy Barrios, MD, PhD1; Carmen Rodríguez, MD1; Alfonso Muriel, PhD18; Laurent Bertoletti, MD, PhD19; Francis Couturaud, MD, PhD20; Menno Huisman, MD, PhD21; José Luis Lobo, MD10; Roger D. Yusen, MD22; Behnood Bikdeli, MD, MS23,24,25; Manuel Monreal, MD, PhD3,26; Remedios Otero, MD, PhD3,6; for the SLICE Trial Group
doi : 10.1001/jama.2021.14846
JAMA. 2021;326(13):1277-1285
Active search for pulmonary embolism (PE) may improve outcomes in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).
Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018
Jiang He, MD, PhD1,2,3; Zhengbao Zhu, MD, PhD1,4; Joshua D. Bundy, PhD, MPH1,2; Kirsten S. Dorans, ScD1,2; Jing Chen, MD, MSc1,2,3; L. Lee Hamm, MD1,2,3
doi : 10.1001/jama.2021.15187
JAMA. 2021;326(13):1286-1298
After decades of decline, the US cardiovascular disease mortality rate flattened after 2010, and racial and ethnic differences in cardiovascular disease mortality persisted.
US Emergency Department Visits Attributed to Medication Harms, 2017-2019
Daniel S. Budnitz, MD, MPH1; Nadine Shehab, PharmD, MPH1,2; Maribeth C. Lovegrove, MPH1; Andrew I. Geller, MD1; Jennifer N. Lind, PharmD, MPH1; Daniel A. Pollock, MD1
doi : 10.1001/jama.2021.13844
JAMA. 2021;326(13):1299-1309
Assessing the scope of acute medication harms to patients should include both therapeutic and nontherapeutic medication use.
Mask-Wearing Behavior at the 2021 NCAA Men’s Basketball Tournament
Joshua R. Vest, PhD, MPH1,2; Justin Blackburn, PhD1; Shama Cash-Goldwasser, MD, MPH3; Eleanor Peters Bergquist, PhD, MSPH, MA3; Peter J. Embi, MD, MS2,4
doi : 10.1001/jama.2021.14057
JAMA. 2021;326(13):1324-1325
Physician Practice Interruptions in the Treatment of Medicare Patients During the COVID-19 Pandemic
Hannah T. Neprash, PhD1; Michael E. Chernew, PhD2
doi : 10.1001/jama.2021.16324
JAMA. 2021;326(13):1325-1328
Strengthening Global Health Security and Reforming the International Health RegulationsMaking the World Safer From Future Pandemics
Antony J. Blinken, JD1; Xavier Becerra, JD2
doi : 10.1001/jama.2021.15611
JAMA. 2021;326(13):1255-1256
An International Agreement on Pandemic Prevention and Preparedness
Lawrence O. Gostin, JD1; Sam F. Halabi, JD, MPhil1; Kevin A. Klock, JD2
doi : 10.1001/jama.2021.16104
JAMA. 2021;326(13):1257-1258
Holding Hope for Patients With Serious Illness
Abby Rosenberg, MD, MS, MA1,2,3; Robert M Arnold, MD4,5; Yael Schenker, MD, MAS4,5
doi : 10.1001/jama.2021.14802
JAMA. 2021;326(13):1259-1260
Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide
Jared R. Lowe, MD1,2; Laura C. Hanson, MD, MPH2,3
doi : 10.1001/jama.2021.9846
JAMA. 2021;326(13):1263-1265
Ninth International Congress on Peer Review and Scientific PublicationCall for Abstracts
John P. A. Ioannidis, MD, DSc1,2; Michael Berkwits, MD, MSCE3; Annette Flanagin, RN, MA3; Fiona Godlee, MBBChir4; Theodora Bloom, PhD4
doi : 10.1001/jama.2021.16596
JAMA. 2021;326(13):1265-1267
Eosinophilic EsophagitisA Review
Amanda Muir, MD, MSTR1; Gary W. Falk, MD, MS2
doi : 10.1001/jama.2021.14920
JAMA. 2021;326(13):1310-1318
Eosinophilic esophagitis (EoE) is a chronic immune-mediated inflammatory disease of the esophagus that affects an estimated 34.4/100?000 people in Europe and North America. EoE affects both children and adults, and causes dysphagia, food impaction of the esophagus, and esophageal strictures.
Infectious Keratitis in 2021
Marlene L. Durand, MD1,2; Miriam Baron Barshak, MD1; James Chodosh, MD, MPH2
doi : 10.1001/jama.2021.0424
JAMA. 2021;326(13):1319-1320
Inferior Vena Cava Filters for the Treatment of Patients With Venous Thromboembolic Disease
Osman Ahmed, MD1; Adam S. Cifu, MD1; Jonathan Paul, MD1
doi : 10.1001/jama.2021.9262
JAMA. 2021;326(13):1321-1322
How COVID-19 Made It Even Tougher to Know ICU Patients as Individuals
Rita Rubin, MA
doi : 10.1001/jama.2021.13462
JAMA. 2021;326(13):1241-1243
Choose ARBs Over ACE Inhibitors for First-line Hypertension Treatment, Large New Analysis Suggests
Jennifer Abbasi
doi : 10.1001/jama.2021.14017
JAMA. 2021;326(13):1244-1245
Pediatric Depression and Anxiety Doubled During the Pandemic
Anita Slomski
doi : 10.1001/jama.2021.16374
JAMA. 2021;326(13):1246
Cycling May Lower Mortality Risk in People Who Have Diabetes
Anita Slomski
doi : 10.1001/jama.2021.15425
JAMA. 2021;326(13):1246
Oral Upadacitinib Beats Subcutaneous Dupilumab for Atopic Dermatitis
Anita Slomski
doi : 10.1001/jama.2021.16375
JAMA. 2021;326(13):1246
Study Projects Lifetime Benefits of Dapagliflozin in HFrEF
Anita Slomski
doi : 10.1001/jama.2021.16376
JAMA. 2021;326(13):1246
Mandated Education for Opioid Prescribers Is Up for Discussion
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.16443
JAMA. 2021;326(13):1247
A First in Stroke Rehabilitation
Rebecca Voelker, MS
doi : 10.1001/jama.2021.16089
JAMA. 2021;326(13):1247
FDA Reaches a Milestone in Generic Drug Approvals
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.16444
JAMA. 2021;326(13):1247
Japanese Medical Mnemonics—Language, Reflection, and Art
Nick Love, MD, PhD1,2,3; Yuichi J. Shimada, MD, MPH4
doi : 10.1001/jama.2021.6972
JAMA. 2021;326(13):1238-1240
Intermittent Fasting
Zhaoping Li, MD, PhD1; David Heber, MD, PhD1
doi : 10.1001/jama.2020.15140
JAMA. 2021;326(13):1338
US Preventive Services Task Force Recommendation Statement on Screening for Colorectal Cancer
Shida Haghighat, MD, MPH1; Daniel A. Sussman, MD, MSPH1; Amar Deshpande, MD1
doi : 10.1001/jama.2021.13466
JAMA. 2021;326(13):1328
US Preventive Services Task Force Recommendation Statement on Screening for Colorectal Cancer—Reply
Michael J. Barry, MD1; Karina Davidson, PhD, MASc2; Carol M. Mangione, MD, MSPH3
doi : 10.1001/jama.2021.13469
JAMA. 2021;326(13):1328-1329
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
Kevin Cowart, PharmD, MPH1; Nicholas W. Carris, PharmD1
doi : 10.1001/jama.2021.13472
JAMA. 2021;326(13):1329-1330
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
Wellbert Hernández-Núñez, MD1; Jesús Zacarías Villareal-Pérez, MD2; René Rodríguez-Gutiérrez, MD, MSc, PhD3
doi : 10.1001/jama.2021.13475
JAMA. 2021;326(13):1330
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin—Reply
Thomas W. Martens, MD1; Roy W. Beck, MD, PhD2; Richard M. Bergenstal, MD3
doi : 10.1001/jama.2021.13478
JAMA. 2021;326(13):1330-1331
